Victoria Socha

DocwireNews

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic kidney disease. ADPKD is associated with a risk for progression to loss of kidney function and kidney failure. Tolvaptan has been approved to slow decline in kidney function in adults with rapidly progressing ADPKD.The FDA Risk Evaluation and Mitigation Strategy program closely monitors the potential risk of liver injury in patients treated with tolvaptan. Sasikiran Nunna, PhD, Otsuka Pharmaceutical Development &amp; Commercialization, Inc, and colleagues conducted a study to examine the safety profile of tolvaptan related to liver function using the number needed to harm (NNH) approach. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2022 in a poster titled Number Needed to Harm (NNH) Analysis of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD).The analysis utilized individual patient-level data from the TEMPO 3:4 trial to assess abnormalities in liver function, and serious alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation adverse events over 12 and 36 months of treatment. Abnormalities in liver function were defined as ALT &gt;3 times and &gt;5 times of the normal&nbsp; range. The reciprocal of the difference in the proportion of patients experiencing a given outcome between tolvaptan and placebo was used to calculate NNH.The cohort included 961 patients in the tolvaptan arm and 483 in the placebo arm. The NNHs for ALT &gt;3 times the upper level of normal were 56.19 (95% CI, 33.60-171.33) over 12 months and 39.81 (95%cI, 25.59-89.57) over 24 months. For every 100 patients treated with tolvaptan rather than placebo, only 1.78 and 2.51 additional patients would&nbsp; have ALT &gt;3 times the upper level of normal over 12 and 24 months, respectively.There were no statistically significant differences between the two study arms in the proportion of patients with ALT &gt;5 times the upper level of normal or serious ALT or AST elevation in either time period. The results suggest that for every 100 patients treated with tolvaptan rather than placebo, fewer than one additional patient would experience ALT &gt;5 times the upper level of normal or serious ALT or AST elevation over 12 or 24 months.&ldquo;The large NNH values help further characterize the safety profile of tolvaptan by demonstrating an acceptable benefit -risk profile,&rdquo; the researchers said.Source: Nunna S, Betts Kam Kumar RK, Nie X, Fernandes A. Number needed to harm (NNH) analysis of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). TH-PO411. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 3, 2022; Orlando, Florida. Support was provided by Otsuka Pharmaceutical Development &amp; Commercialization, Inc.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Acceptable Benefit-Risk Profile of Tolvaptan in Number Needed to Harm Analysis

ADPKD

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic kidney disease. ADPKD is associated with a risk for progression to loss of kidney function ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe